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Abstract
Background/Objectives
Obesity has been linked to morbidity and mortality through increased risk for many chronic
diseases. Endothelin (EDN) system has been related to endothelial function but it can be in-
volved in lipid metabolism regulation: Receptor type A (EDNRA) activates lipolysis in adipo-
cytes, the two endothelin receptors mediate arsenic-stimulated adipocyte dysfunction, and
endothelin system can regulate adiposity by modulating adiponectin activity in different situ-
ations and, therefore, influence obesity development. The aim of the present study was to
analyze if single nucleotide polymorphisms (SNPs) in the EDN system could be associated
with human obesity.
Subjects/Methods
We analyzed two samples of general-population-based studies from two different regions of
Spain: the VALCAR Study, 468 subjects from the area of Valencia, and the Hortega Study,
1502 subjects from the area of Valladolid. Eighteen SNPs throughout five genes were ana-
lyzed using SNPlex.
Results
We found associations for two polymorphisms of the EDNRB gene which codifies for EDN
receptor type B. Genotypes AG and AA of the rs5351 were associated with a lower risk for
obesity in the VALCAR sample (p=0.048, OR=0.63) and in the Hortega sample (p=0.001,
OR=0.62). Moreover, in the rs3759475 polymorphism, genotypes CT and TT were also as-
sociated with lower risk for obesity in the Hortega sample (p=0.0037, OR=0.66) and in the
VALCAR sample we found the same tendency (p=0.12, OR=0.70). Furthermore, upon
studying the pooled population, we found a stronger association with obesity (p=0.0001,
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OR=0.61 and p=0.0008, OR=0.66 for rs5351 and rs3759475, respectively). Regarding
plasma arsenic levels, we have found a positive association for the two SNPs studied with
obesity risk in individuals with higher arsenic levels in plasma: rs5351 (p=0.0054, OR=0.51)
and rs3759475 (p=0.009, OR=0.53)
Conclusions
Our results support the hypothesis that polymorphisms of the EDNRB gene may influence
the susceptibility to obesity and can interact with plasma arsenic levels.
Introduction
Obesity is a state in which excess lipids accumulate in various body fat depots due to a chronic
imbalance between energy intake and energy expenditure [1]. The prevalence of obesity is in-
creasing. It is the most frequent metabolic disease, reaching epidemic proportions in industrial-
ized countries [2]. Obesity significantly increases the risk of chronic diseases such as type 2
diabetes, cardiovascular disease, nonalcoholic fatty liver disease, colon cancer and obstructive
sleep apnea [3].
Obesity is a proinflammatory condition in which both hypertrophied adipocytes and adi-
pose tissue-resident immune cells (primarily lymphocytes and macrophages) contribute to the
alteration of circulating levels of different molecules, including endothelins, affecting almost all
tissues [4–7]. In obesity, endothelin system has an important role in endothelial dysfunction
[8–9], and this may influence adipose tissue development [10].
The endothelin (EDN) system consists of three endothelin isoforms (EDN1, EDN2 and
EDN3), and two receptors (endothelin type A and type B) linked to multiple signaling path-
ways [11]. Endothelins (EDN1, EDN2 and EDN3) are 21-amino acid peptides that exert their
effects through their cognate receptors EDNRA and EDNRB.
EDNRA has high affinities for EDN1 and EDN2 and 100-fold lower affinity for EDN3,
while EDNRB demonstrates equal affinities for all ligands [12,13]. Activation of EDNRA and
EDNRB mediates many important functions, including vasoconstriction, cardiovascular re-
modeling, cell proliferation, cell differentiation, extracellular matrix production, and control of
water and sodium secretion [13–15]. Although the pathophysiological role of EDNRA and
EDNRB has not yet been completely elucidated, EDNRA is considered a bad receptor involved
in pathogenesis and the development of various diseases as systemic and pulmonary hyperten-
sion, atherosclerosis, diabetes, and cardiac remodeling after myocardial ischemia [13, 15, 16].
EDNRB, however, has been classified as a good receptor since it functions as a “clearance re-
ceptor” preventing EDN1 from excessively stimulating EDNRA and enhancing endothelial
production of nitric oxide (NO) and prostacyclin (PGI2) causing vasodilatation [16].
Endothelin can regulate adiponectin levels in different situations and therefore influence
obesity development [10,17,18]. In addition, it has been described that EDNRA activates lipol-
ysis in adipocytes [19], and the endothelin receptors mediate arsenic-stimulated adipocyte dys-
function [20]. Arsenic exposure has been linked to increased metabolic disease and alterations
in lipid handling in adipose tissue [20, 21–25] and part of these alterations can be produced by
an effect on EDN receptors inhibition [20, 26].
These data may indicate a role of the EDN system in obesity, and its genetic variation can
modulate or be associated with obesity. Most genetic association studies of the EDN system
have focused on other aspects, like the relationship with cardiovascular implications [27],
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asthma [28] and intracranial aneurysms [29, 30], but have not analyzed its relationship with
obesity. Therefore, the aim of the present study was to analyze whether single nucleotide poly-
morphisms (SNPs) in the EDN system could be associated with human obesity.
Material and Methods
Population samples
We have analyzed two collections of general-population-based studies from two different re-
gions of Spain: the VALCAR Study, with 468 subjects from the area of Valencia, and the Hor-
tega Study, with 1502 subjects from the area of Valladolid. The sample tested included 1970
persons in total. The Hortega Study was approved by the Ethical Committee of Hospital Río
Hortega, VALCAR Study and present genetic studies were approved by the Ethical Commit-
tee of Hospital Clínico Universitario de Valencia. All participants gave and signed their
informed consent.
Demographic data (age and gender) along with anthropometric parameters were collected
using standard procedures. The presence of obesity, hypertension (HTN) and type 2 diabetes
was registered. BMI was calculated (kg/m2). Obesity, HTN and type 2 diabetes were defined
using the World Health Organization (WHO) criteria (http://www.who.int). Briefly, obesity
was diagnosed when a BMI value was30 kg/m2. HTN was defined when systolic and diastolic
blood pressure values were>140 or 90 mm Hg, respectively. The current WHO diagnostic cri-
teria for diabetes were applied (http://www.who.int/diabetes/action_online/basics/en/index1.
html): fasting plasma glucose7.0mmol/l (126mg/dl) or 2 h plasma glucose11.1mmol/l
(200mg/dl). A previous diagnosis of type 2 diabetes or HTN and detection of the disease at the
moment of sample collection was registered. Metabolic syndrome was defined by the National
Cholesterol Education Program—Adult Treatment Panel (NCEP-ATP III) criteria [31] and by
International Diabetes Federation IDF criteria [32].
Table 1 includes the general characteristics of the samples analyzed.
The exclusion criteria were the same in both populations: the presence of serious concomi-
tant diseases or disorders that could influence the collection of reliable information and any
mental or social condition which might complicate or prevent the subject from participating in
the study.
SNP selection and genotyping
Venous blood samples were collected in tubes containing EDTA to obtain genomic DNA by
the Chemagic system (Chemagen, Baesweiler, Germany). DNA was quantified and diluted to a
final concentration of 100 ng ⁄μL.
EDN system SNPs for genotyping were selected based on the conjunction of several param-
eters by SYSNPs [33]: heterozygosity (>10% for the minor allele frequency) in a Caucasian
population, position and spacing along the gene, and possible functional effect (http://www.
ensembl.org/index.html). Eighteen SNPs from five genes were finally selected (Table 2). The
SNPs were genotyped using an oligonucleotide ligation assay (SNPlex; Applied Biosystems,
Foster City, CA, USA) following the manufacturer’s guidelines.
Plasma Arsenic Level Assessment
Total arsenic was measured in the Hortega Study following a standardized protocol by induc-
tively coupled-plasma mass spectrometry (ICPMS) with an Agilent 7500CEx ICPMS (Agilent
Tecnologies, United States). The detection limit for arsenic plasma levels was 20.0 nmol/L.
Endothelin SystemGenes, Arsenic Levels and Obesity
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Statistical analysis
Samples with low genotyping results (<90%) were removed for all SNPs. All quantitative val-
ues are expressed as mean ± standard deviation or as (n, %) when describing qualitative vari-
ables. The ANOVA test was used to compare quantitative variables between groups and the
chi-square test for categorical variables.
Allele and genotype frequencies were calculated for each SNP using SPSS and SNPSTATS
(http://bioinfo.iconcologia.net/index.php). The Hardy—Weinberg equilibrium (HWE) was
performed using a chi-square distribution with one degree of freedom using SNPSTAT soft-
ware. The HWE was maintained for all the polymorphisms analyzed.
The association between polymorphisms and anthropometric parameters, BMI as a quanti-
tative trait, and obesity as a qualitative trait, were examined first using a co-dominant inheri-
tance model by SPSS and SNPSTAT, and afterward by the remaining models if two genotypes
had similar means. The ANOVA procedure was used to compare mean differences for contin-
uous variables among genotypes. The association of obesity with each polymorphism and hap-
lotypes was sought using logistic regression models. Linkage disequilibrium measurements
were calculated using the R2 statistic. The odds ratios (OR) were used to evaluate the risk for
the presence of obesity for each polymorphism. Age and gender, as two potential confounders,
were used as covariates. For multiple analysis corrections using Bonferroni correction, the p-
value limit for significance for the study of 18 polymorphisms was 0.0027.
Results
Characteristics of the study population
The association between polymorphisms of the EDN system genes and the obesity traits was
first analyzed in the VALCAR population. Positive results were analyzed in a second popula-
tion, Hortega. Finally, the association was analyzed in all samples together.
Table 1. General characteristics of the population.
Characteristic Valcar Hortega Valcar + Hortega
No. Of subjects 468 1502 1970
Age (years) 46.4 ± 14.9 54.4 ± 19.3* 52.6 ± 18.7
BMI (kg/m2) 28 ± 4.7 26.4 ± 4.1* 27.7 ± 4.4
Waist circumference (cm) 92.6 ± 12.8 89.5 ± 13.0* 90.2 ± 13.0
Obesity (n, %) 114 (24.8) 356 (23.7) * 470 (23.9)
Abdominal obesity (n, %) 151 (32.8) 414 (27.6) * 565 (28.8)
Diabetes mellitus (n, %) 55 (11.9) 114 (7.6) * 169 (8.6)
Glucose (mg/dL) 99.7 ± 24.4 92.5 ± 20.4* 91.9 ± 29.9
Hypertension (n, %) 129 (26.7) 642 (42.7) * 771 (39.3)
Systolic blood pressure (mmHg) 126.5 ± 16.1 130.7 ± 21.6* 129.5 ± 20.5
Diastolic blood pressure (mmHg) 77.1 ± 9.9 79.1 ± 10.6* 78.2 ± 10.4
Total cholesterol (mg/dL) 222.7 ± 61.7 201.3 ± 38.1* 207.6 ± 46.2
HDL cholesterol (mg/ dL) 56.4 ± 15.1 51.7 ± 14.2* 53.9 ± 14.5
Triglycerides (mg/ dL) 123.4 ± 163.3 153.1 ± 113.8* 145.5 ± 127.4
Metabolic syndrome (n, %)
IDF criteria 171 (36.5) 588 (39.1)* 759 (38.5)
ATP III criteria 148 (31.6) 480 (31.9) 628 (31.9)
Values are mean ± standard deviation. For qualitative variables, data are expressed as (n, %)
* p-value < 0.0001
doi:10.1371/journal.pone.0118471.t001
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The main characteristics of the two populations studied are shown in Table 1. The Valcar
Study included 468 individuals (24.80% obese; 47.22% men) and the Hortega Study included
1502 subjects (23.70% obese; 49.47% men).
Association of EDN system gene polymorphisms with obesity
Of all the polymorphisms, only two located in the EDNRB gene (rs5351 and rs3759475) were
associated with obesity (Table 3). Polymorphisms with p<0.15 were selected and studied in
Hortega Sample. Genotypes AG and AA of the rs5351 were associated with a lower risk for
obesity in the Hortega sample (OR = 0.63; p = 0.048) and genotypes CT and TT of rs3759475
showed a tendency to lower risk for obesity (OR = 0.70; p = 0.12). These two polymorphisms
showed similar results in VALCAR sample: genotypes AG and AA of rs5351 were associated
with reduced risk of obesity (OR = 0.62; p = 0.001). Moreover, in the rs3759475 polymorphism,
genotypes CT and TT were also associated with lower risk for obesity (OR = 0.66; p = 0.0037).
Furthermore, upon studying the pooled population, we found a stronger association with
obesity (p = 0.0001 and 0.0008 for rs5351 and rs3759475, respectively). We observed a slight
tendency for association with lower BMI with the same genotypes.
Table 2. Characteristics of selected Polymorphisms.
Chr HGN Gene name Ensemble ID SNP name Chr
position
Reference % Genotype HW MAF Allele
Reference vs
minor
6 EDN1 Endothelin 1 ENSG00000078401 rs1800541 12397205 NM_001955.4:c.-1644T>G 97.7 0.032 0.228 T>G
rs3087459¥ 12397625 NM_001955.4:c.-1224A>C 98.3 0.021 0.187 A>C
rs2070699¥ 12400758 NM_001955.4:c.233
+30G>T
97.7 0.957 0.401 G>T
rs5370¥ 12404241 NM_001955.4:c.594G>T 98.5 0.170 0.206 G>T
1 EDN2 Endothelin 2 ENSG00000127129 rs11210262 41716731 NM_001956.3:c.*936G>C 97.0 0.476 0.072 G>C
rs11572340¥ 41723492 NM_001956.3:c.-633G>T 98.1 0.199 0.130 G>T
20 EDN3 Endothelin 3 ENSG00000124205 rs260741¥ 57309550 NM_000114.2:c.52
+236G>A
99.0 0.710 0.200 C>T
rs11570257 57310195 NM_000114.2:c.365
+23G>A
99.6 1.00 0.016 G>A
4 EDNRA Endothelin
receptor type A
ENSG00000151617 rs6842241¥ 148620269 NM_001957.3:c.-1780C>A 97.3 0.123 0.247 C>A
rs1801708 148621819 NM_001957.3:c.-230G>A 96.6 0.387 0.464 G>A
rs5333 148680487 NM_001957.3:c.969T>C 99.5 0.256 0.326 T>C
rs5334 148680523 NM_001957.3:c.1005G>A 98.3 0.440 0.326 G>A
rs5335 148683290 NM_001957.3:c.*70G>C 98.9 0.927 0.499 G>C
rs5342¥ 148684221 NM_001957.3:c.*1001A>G 97.9 0.310 0.353 A>G
13 EDNRB Endothelin
receptor type B
ENSG00000136160 rs5352 77373231 NM_001201397.1:
c.1184G>A
99.7 0.085 0.007 G>A
rs5351 77373314 NM_001201397.1:
c.1101A>G
99.4 0.788 0.451 G>A
rs12716722¥ 77390857 NM_001201397.1:c.220–
97A>G
99.9 0.935 0.062 A>G
rs3759475 77393106 NM_001201397.1:c.-
1355T>C
99.7 0.604 0.500 C>T
HGN, The HUGO Gene Nomenclature.
¥:Tag-SNP by Hapmap in Caucasian patients. Ensemble ID: Ensemble human release 53. SNP name: dbSNP129 (NCBI´s build 36, version 3)
doi:10.1371/journal.pone.0118471.t002
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Association of EDN system gene polymorphisms with central obesity
and other parameters
We have found a slight significant association with waist circumference of both polymor-
phisms when corrected by age and sex in Hortega sample but not in VALCAR study (see
S1 Table). When we include BMI in the analysis the significance is lost.
Otherwise we have not found any association between EDNRB polymorphisms and other
parameters as metabolic syndrome, HOMA-IR or glucose levels.
Haplotype analysis
Haplotype analysis was done with rs5351 and rs3759475 SNPs. One of the haplotypes includ-
ing the two alleles associated with reduced risk of obesity, called number two in Table 4, was as-
sociated with lower risk for obesity. It was present in 40% of the individuals. These two
Table 3. Association between obesity and BMI and SNPs of EDNRB genes adjusted by age and sex in: A-Valcar Study / B-Hortega Study / C-
Both.
EDNRB dbSNP*/Reference Genotype N BMI % non obese % obese Obesity OR (95% CI)
Gene
A)
rs5351
HWE: 0.7881 GG 154 27.43 (0.36) 105 (34.4%) 49 (46.2%) 1.00
MAF: 0.451 AG-AA 257 27.45 (0.3) 200 (65.6%) 57 (53.8%) 0.63 (0.40–0.99)
P-value 0.65 0.048
rs3759475
HWE: 0.6045 CC 149 27.35 (0.37) 103 (33.8%) 46 (43.4%) 1.00
MAF: 0.500 CT-TT 262 27.49 (0.3) 202 (66.2%) 60 (56.6%) 0.70 (0.44–1.10)
P-value 0.41 0.12
B)
rs5351
HWE: 0.7881 GG 480 26.64 (0.21) 372 (31.9%) 108 (42.2%) 1.00
MAF: 0.451 AG-AA 942 26.27 (0.13) 794 (68.1%) 148 (57.8%) 0.62 (0.47–0.83)
P-value 0.08 0.001
rs3759475
HWE: 0.6045 CC 487 26.63 (0.21) 379 (32.6%) 108 (41.7%) 1.00
MAF: 0.500 CT-TT 935 26.32 (0.13) 784 (67.4%) 151 (58.3%) 0.66 (0.49–0.87)
P-value 0.14 0.0037
C)
rs5351
HWE: 0.7881 GG 634 26.83 (0.18) 477 (32.4%) 157 (43.4%) 1.00
MAF: 0.451 AG-AA 1199 26.52 (0.12) 994 (67.6%) 205 (56.6%) 0.61 (0.48–0.78)
P-value 0.12 1,00E-04
rs3759475
HWE: 0.6045 CC 636 26.8 (0.18) 482 (32.8%) 154 (42.2%) 1.00
MAF: 0.500 CT-TT 1197 26.57 (0.12) 986 (67.2%) 211 (57.8%) 0.66 (0.52–0.84)
P-value 0.29 8,00E-04
HWE, Hardy—Weinberg equilibrium; MAF, minor allele frequency; SNP, single-nucleotide polymorphism; OR, odds ratio. Values are mean ± standard
error. Bold indicates signiﬁcance.
*dbSNP 129.
doi:10.1371/journal.pone.0118471.t003
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polymorphisms have a high linkage disequilibrium (D´ = 0.967). Fig. 1 shows the linkage dis-
equilibrium plots of the four studied EDNRB SNPs.
Association modulated by arsenic levels
We divided the Valladolid sample into tertiles by plasma arsenic levels, from individuals with
lower arsenic levels (20 nmol/L), intermediate levels (>20 nmol/L and<50 nmol/L) and in-
dividuals with higher levels (50 nmol/L). We have observed a similar BMI media value in
higher and medium arsenic serum levels tertiles (26.8 ± 4.1 kg/m2 and 26.5 ± 4.2 kg/m2 respec-
tively). However lower arsenic serum levels tertil is associated with lower BMI media value
(25.9 ± 4.3 kg/m2; p = 0.037; p = 0.002 and p = 0.003, when compared with second, third and
with second and third tertiles together. In the analysis of the association of the rs5351 and
rs3759475 polymorphisms with BMI and obesity, we found a trend for association of genotypes
AG-AA of rs5351 and CT-TT of rs3759475 with lower BMI and a significant association with
lower risk for obesity in individuals with higher arsenic levels, but not with those of medium or
lower levels (see Table 5). In all cases, there is a similar trend. But in those with higher levels,
Table 4. Haplotype association analysis of rs5351 and rs3759475 of EDNRB gene with BMI and obesity risk adjusted by age and sex.
Frequency BMI
No. Haplotype Non-obese Obese Freq OR (95% CI) P-value Difference (95% CI) P-value
1 GC 0.566 0.635 0.580 1.00 — 0.00 —
2 AT 0.418 0.347 0.403 0.73 (0.61–0.87) 4,00E-04 -0.22 (-0.49–0.05) 0.11
3 GT + AC 0.015 0.018 0.016 0.99 (0.52–1.88) 0.97 -0.32 (-1.39–0.74) 0.55
Single nucleotide polymorphisms used in the haplotype construction: rs5351, rs3759475.
doi:10.1371/journal.pone.0118471.t004
Fig 1. Linkage Disequilibrium (LD) plot of studied EDNRB SNPs. a) D´ b) R2.
doi:10.1371/journal.pone.0118471.g001
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the effect is stronger (the OR for rs5351 and for a population with higher levels is 0.50, and for
the other groups it is 0.70; in rs3759475 the values are 0.50, 0.77 and 0.70 in the higher levels to
the lower levels, respectively). Moreover, analysis by As tertiles do not show an association be-
tween ENDRB polymorphisms and waist.
Haplotype analysis in relation to arsenic levels
Haplotype analysis in the tertiles based on arsenic levels were performed for the rs5351 and
rs3759475 SNPs (Table 6). Haplotype 2 remains associated with lower obesity risk only in the
higher arsenic level group.
Discussion
We have genotyped eighteen polymorphisms located in the five genes of the EDN system and
we have analyzed their association with BMI and obesity. We have found an association for
Table 5. Relation with Arsenic serum levels.
1- Association with rs5351 (NM_001201397.1:c.1101A>G) of EDNRB gene.
Genotype N BMI % non obese % obese Obesity OR (95% CI)
A) Individuals with high arsenic levels
GG 157 27.15 (0.36) 115 (30.4%) 42 (43.8%) 1.00
AG-AA 319 26.59 (0.22) 265 (69.6%) 54 (56.2%) 0.51 (0.32–0.82)
0.08 0.0054
B) Individuals with medium arsenic levels
GG 170 26.77 (0.35) 133 (34.2%) 37 (43.0%) 1.00
AG-AA 305 26.32 (0.23) 256 (65.8%) 49 (57.0%) 0.70 (0.43–1.13)
0.29 0.15
C) Individuals with low arsenic levels
GG 152 25.98 (0.37) 123 (31.1%) 29 (38.7%) 1.00
AG-AA 318 25.92 (0.23) 272 (68.9%) 46 (61.3%) 0.70 (0.41–1.20)
0.71 0.20
2- Association with rs3759475 (NM_001201397.1:c.-1355T>C) of EDNRB gene.
Genotype N BMI % non obese % obese Obesity OR (95% CI)
A) Individuals with high arsenic levels
CC 164 27.21 (0.34) 120 (32.0%) 44 (44.9%) 1.00
CT-TT 310 26.65 (0.22) 256 (68.0%) 54 (55.1%) 0.53 (0.33–0.85)
0.093 0.009
B) Individuals with medium arsenic levels
CC 167 26.73 (0.35) 132 (33.8%) 35 (40.2%) 1.00
CT-TT 311 26.37 (0.22) 259 (66.2%) 52 (59.8%) 0.77 (0.47–1.25)
0.39 0.30
C) Individuals with low arsenic levels
CC 155 25.90 (0.37) 126 (32.0%) 29 (38.7%) 1.00
CT-TT 314 25.96 (0.23) 268 (68.0%) 46 (61.3%) 0.70 (0.41–1.21)
0.79 0.20
Association between obesity and BMI and SNPs of EDNRB genes adjusted by age and sex. OR, odds ratio. Values are mean ± standard error. Bold
indicates signiﬁcance.
doi:10.1371/journal.pone.0118471.t005
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two polymorphisms of the EDNRB gene with obesity. Genotypes AG and AA of the rs5351
were associated with a lower risk for obesity in both samples and overall when we analyzed the
pooled sample. Moreover, in the rs3759475 polymorphism, genotypes CT and TT showed a
trend for lower risk in the VALCAR sample and were associated with a lower risk for obesity in
the Hortega population. The effect increased when the samples were analyzed together. Re-
garding the BMI data, we have found a trend congruent with these results although the values
do not reach statistical significance. Otherwise our data show the absence of association of
rs5351 and rs3759475 with waist or abdominal obesity although we have found a slight associa-
tion lost when BMI is included as a covariable in the analysis.
We have analyzed if EDNRB polymorphisms were associated with glucose levels and meta-
bolic syndrome (defined by ATP III and IDF criteria) and we have not found any association
of rs5351 and rs3759475 with these parameters. These data could indicate the possible impor-
tance of these polymorphisms in obesity risk but not in metabolic complications, although spe-
cific studies focused in these parameters should be done to clarify this point.
It is remarkable that although the Hortega and VALCAR populations had different charac-
teristics, the findings were replicated and the analysis of whole sample showed a stronger asso-
ciation. As noted in Table 4, a haplotype associated with a lower risk for obesity and which is
frequent in the population, is congruent with the data obtained in individual polymorphism
analysis (haplotype AT for rs5351 and rs3759475).
The functional significance of these two SNPs is not clear. SNP rs5351 is located in exon 6,
it is a synonymous variation in this gene, and it is present in the transcript of EDNRB antisense
Table 6. Haplotype association analysis of rs5351 and rs3759475 of EDNRB gene with BMI and obesity risk adjusted by age and sex in relation
with Arsenic serum levels.
A) Individuals with higher Arsenic serum levels.
Frequency BMI
No. Haplotype Non-obese Obese Freq OR (95% CI) P-value Difference (95% CI) P-value
1 GC 0.549 0.678 0.576 1.00 — 0.00 —
2 AT 0.430 0.306 0.405 0.53 (0.37–0.76) 6,00E-04 -0.49 (-1.01–0.02) 0.06
3 AC 0.012 0.010 0.012 0.66 (0.13–3.28) 0.62 0.02 (-2.35–2.39) 0.99
4 GT 0.008 0.005 0.007 0.78 (0.09–6.72) 0.82 -0.32 (-3.24–2.6) 0.83
B) Individuals with medium Arsenic serum levels.
Frequency BMI
No. Haplotype Non-obese Obese Freq OR (95% CI) P-value Difference (95% CI) P-value
1 GC 0.580 0.620 0.587 1.00 — 0.00 —
2 AT 0.402 0.356 0.393 0.84 (0.59–1.20) 0.34 -0.27 (-0.79–0.25) 0.31
3 AC 0.008 0.006 0.007 0.69 (0.08–6.05) 0.74 -2.05 (-5.01–0.91) 0.18
4 GT 0.010 0.018 0.012 2.00 (0.49–8.11) 0.33 0.27 (-2.1–2.64) 0.82
C) Individuals with lower Arsenic serum levels.
Frequency BMI
No. Haplotype Non-obese Obese Freq OR (95% CI) P-value Difference (95% CI) P-value
1 GC 0.551 0.599 0.558 1.00 — 0.00 —
2 AT 0.435 0.395 0.429 0.82 (0.56–1.19) 0.29 -0.13 (-0.62–0.36) 0.61
3+4 AC+GT 0.014 0.007 0.013 0.30 (0.04–2.52) 0.27 -1.96 (-4.19–0.27) 0.08
Single nucleotide polymorphisms used in the haplotype construction: rs5351, rs3759475.
doi:10.1371/journal.pone.0118471.t006
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RNA 1 (EDNRB-AS1) without a known function. And rs3759475 is an intronic variation. Nev-
ertheless, it should be noted that both have a MAF>0.40, and that they have a high linkage dis-
equilibrium (D´ = 0.967). There are no studies including the associated SNPs found in this
work, except for rs5351, which has been associated with atherosclerosis [27]. Nevertheless,
there are studies that identify EDNRB (and rs5351 in particular), as a gene with significant alle-
lic expression difference. Differential allelic expression can be associated with differences due
to genetic variations or epigenetic mechanisms involved in gene regulation [34]. In addition,
these polymorphisms can be in linkage disequilibrium with functional variations of this gene.
Regarding plasma arsenic levels, we have found an association between increased levels and
higher BMI levels as previously described [35]. We have observed a positive association for the
two SNPs studied (rs5351 and rs3759475) with obesity risk in individuals with higher arsenic
levels. The haplotype analysis showed that the same haplotype found in the pooled population
was associated with a lower risk for obesity in individuals with higher arsenic levels, while there
was no association in those with medium or lower arsenic levels (Table 6). These data show
that arsenic can modulate the effect of the genetic polymorphisms of the EDNRB gene in
modulating obesity.
This association has not been previously found by GWAS studies. These differences may be
the result of different environmental factors in the populations included in the different studies,
like differences in nutrition or in arsenic levels derived from it. Another explanation may come
from the specific situation of a Mediterranean population. Most of the time it is underrepre-
sented in GWAS studies, and many times there is no Spanish sample in these studies [36–38].
Nevertheless, there are other studies in Spanish population of obesity-related genes described
in different populations but FTO was the only locus that was clearly associated with BMI while
the other 22 analyzed were not associated [39]. Considering the high heritability of obesity,
new variants remain to be discovered and, overall, in Spanish population where previously de-
scribed polymorphisms seem not to have the effect previously described.
Most of the work done up to now in relation to the endothelin system and obesity has been
done in relation to increased levels of endothelin in obesity and their possible effects on vascu-
lar tone and endothelial disfunction [40]. Some works indicate that endothelin is involved in
obesity through different mechanisms such as the regulation of blood flow to adipose tissue
[10]. In addition, endothelin system can regulate some hormones involved in adipogenesis and
metabolic processes that can be related to obesity. Thus, endothelin has been identified as a reg-
ulator of adiponectin levels in obese children and as a regulator of adiponectin gene expression
and secretion [17,18]. It also regulates glucose update, glycolysis and lipolysis genes in rats [19,
41–44]. Most of these effects seem to be mediated by EDNRA, while there is little information
about a possible role of EDNRB. Nevertheless, EDNRB has been involved in peripheral micro-
vascular function, cancer development and in the development of different hereditary diseases
like Waardenburg syndrome or Hirschsprung disease and, therefore, EDNRB is also involved
in the alteration of enteric neurons [45–48]. Moreover, this protein is related to the develop-
ment and growth of different tumors [3,4]. All these facts can link this gene with obesity by dif-
ferent pathways (cell differentiation, growth, neuronal processes, etc.). In addition, it has been
described that inhibition of EDNRB protects lipid droplets against the effect of arsenic [20],
which can be associated with the development of obesity. Thus, our results indicate that elevat-
ed arsenic levels modulate the EDNRB association with obesity.
Otherwise EDN system can modulate the toxic effect of arsenic. EDNRA and EDNRB sig-
naling is often cooperative with the formation of heterodimeric signaling complexes suggesting
that arsenic may be acting through a complex of EDNR [20]. Therefore, polymorphisms affect-
ing the activity of EDN receptors by modification of their sequence, their expression levels or
their regulation can be involved in different responses to arsenic exposure. The effect of arsenic
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or the inhibition of these receptors can modulate the perilipin 1 (PLIN1) expression and lipoly-
sis and, therefore, obesity risk and its consequences. All previous data may indicate that activity
of EDN system can modulate the toxic effect of Arsenic.
Limitations of our study
The number of individuals included in the present study is limited, but the statistical power is
sufficient for the polymorphisms analyzed. The number of polymorphisms analyzed is re-
duced, nevertheless we do not expect to study total genetic variability in these genes because
many other polymorphisms may be analyzed in these genes and studies with a higher number
of polymorphisms would be required. We have only measured arsenic levels in one of the sam-
ples, although it is the larger of the two. Finally, the functional meaning of these two SNPs with
a significant association is not clear, and other studies should be performed in order to identify
whether these polymorphisms or others in linkage disequilibrium have a functional effect and
how they can be involved in modulating obesity risk.
In conclusion, our study carried out in two Spanish populations from different regions and
noticeably distinct characteristics supports the hypothesis that polymorphisms of the EDNRB
gene may influence the susceptibility to obesity. In addition, blood arsenic levels can modulate
the influence of these polymorphisms on obesity risk.
Despite this evidence, we should be cautious in the interpretation of the data. The possible
role of SNPs of the EDNRB gene in obesity phenotypes should be confirmed by other studies,
including analyses among different populations, larger sample sizes, etc.
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